SNDX
Company Description
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 172.35M | 23.68M | 0 | 0 | 139.71M | 1.52M | 1.52M | 1.52M | 2.11M | 1.22M | 627,000 | 0 |
| Net Income | (285.42M) | (318.76M) | (209.36M) | (149.34M) | 24.93M | (73.07M) | (55.95M) | (73.96M) | (60.80M) | (44.47M) | (24.12M) | (19.83M) |
| EPS | -3.29 | -3.73 | -2.98 | -2.46 | 0.48 | -1.77 | -1.84 | -2.92 | -2.90 | -3.04 | -4.31 | -2.07 |
| Free Cash Flow | (323.17M) | (274.90M) | (160.60M) | (133.90M) | 29.00M | (71.26M) | (50.61M) | (68.72M) | (47.45M) | (35.42M) | (2.48M) | (14.40M) |
| FCF / Share | -3.73 | -3.21 | -2.28 | -2.20 | 0.56 | -1.73 | -1.66 | -2.71 | -2.26 | -2.42 | -0.44 | -1.50 |
| Operating CF | (322.98M) | (274.90M) | (160.60M) | (133.68M) | 29.13M | (71.26M) | (50.61M) | (68.53M) | (47.37M) | (35.16M) | (2.43M) | (14.39M) |
| Total Assets | 529.71M | 724.82M | 612.88M | 497.24M | 449.66M | 300.61M | 63.52M | 83.94M | 137.19M | 109.01M | 89.90M | 12.82M |
| Total Debt | 346.48M | 345.74M | 1.64M | 1.16M | 20.97M | 20.54M | 897,000 | 0 | 0 | 0 | 0 | 13.88M |
| Cash & Equiv | 134.93M | 154.08M | 295.39M | 74.36M | 221.97M | 115.24M | 24.61M | 33.77M | 35.17M | 23.84M | 23.18M | 10.01M |
| Book Value | 64.63M | 288.12M | 554.20M | 467.45M | 408.37M | 252.19M | 31.60M | 53.05M | 104.32M | 84.14M | 66.70M | (5.72M) |
| Return on Equity | -4.42 | -1.11 | -0.38 | -0.32 | 0.06 | -0.29 | -1.77 | -1.39 | -0.58 | -0.53 | -0.36 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 64.86M | 68.48M | 45.87M | 37.96M | 20.04M | 7.68M | 12.50M | 3.50M | 0 | 0 | 0 | 0 |
| Net Income | (42.67M) | (68.01M) | (60.72M) | (71.85M) | (84.85M) | (94.17M) | (84.13M) | (68.06M) | (72.40M) | (72.47M) | (51.15M) | (44.62M) |
| EPS | -0.49 | -0.78 | -0.70 | -0.83 | -0.99 | -1.10 | -0.98 | -0.80 | -0.85 | -1.00 | -0.73 | -0.64 |
| Free Cash Flow | (50.34M) | (69.54M) | (70.67M) | (87.80M) | (95.16M) | (57.39M) | (62.32M) | (71.64M) | (83.55M) | (41.35M) | (44.65M) | (35.37M) |
| FCF / Share | -0.58 | -0.80 | -0.82 | -1.02 | -1.11 | -0.67 | -0.73 | -0.84 | -0.98 | -0.57 | -0.64 | -0.51 |
| Operating CF | (50.34M) | (69.49M) | (70.53M) | (87.80M) | (95.16M) | (57.39M) | (62.32M) | (71.64M) | (83.55M) | (41.35M) | (44.65M) | (35.37M) |
| Total Assets | 472.67M | 529.71M | 551.79M | 596.15M | 640.71M | 724.82M | 425.81M | 476.95M | 543.03M | 612.88M | 399.22M | 431.34M |
| Total Debt | 345.36M | 346.48M | 345.43M | 1.68M | 1.84M | 345.74M | 854,000 | 1.13M | 1.39M | 1.64M | 1.87M | 2.10M |
| Cash & Equiv | 130.89M | 134.93M | 116.81M | 108.64M | 153.99M | 154.08M | 133.02M | 105.40M | 114.61M | 295.39M | 94.55M | 97.28M |
| Book Value | 41.62M | 64.63M | 115.43M | 157.42M | 215.06M | 288.12M | 366.43M | 434.34M | 491.89M | 554.20M | 359.19M | 400.04M |
| Return on Equity | -1.03 | -1.05 | -0.53 | -0.46 | -0.39 | -0.33 | -0.23 | -0.16 | -0.15 | -0.13 | -0.14 | -0.11 |
